Selective oestrogen receptor

Selective oestrogen receptor modulators (SERMs, e.g. Raloxifene) Calcitriol and analogues (limited use)... [Pg.280]

Jordan VC (2007) Chemoprevention of breast cancer with selective oestrogen-receptor modulators. Nat Rev Cancer 7 46-53... [Pg.1117]

Robertson JFR (2004) Selective oestrogen receptor modulators/new antioestrogens a clinical perspective. Cancer Treat Rev 30 695-706... [Pg.167]

Baumer AT, Wassmann S, Ahlbory K, Strehlow K, Muller C, Sauer H, Bohm M, Nick-enig G (2001) Reduction of oxidative stress and AT 1 receptor expression by the selective oestrogen receptor modulator idoxifene. Br J Pharmacol 134 579-584... [Pg.238]

Albertazzi P, Purdie DW. Oestrogen and selective oestrogen receptor modulators (SERMs) current roles in the prevention and treatment of osteoporosis. Best Pract Res Clin Rheumatol 2001 15(3) 451-68. [Pg.300]

Goldstein SR, Siddhanti S, Ciaccia AV, Plouffe L Jr. A pharmacological review of selective oestrogen receptor modulators. Hum Reprod Update 2000 6(3) 212-24. [Pg.300]

Compston JE. Selective oestrogen receptor modulators potential therapeutic applications. Clin Endocrinol (Oxf) 1998 48(4) 389-91. [Pg.300]

Nilsson S et al (2005) Oestrogen receptors and selective oestrogen receptor modulators molecular and cellular pharmacology. Basic Clin Pharmacol Toxicol 96 15-25... [Pg.246]

As previously mentioned, despite the benefits of tamoxifen in the treatment of breast cancer, it is known to increase the risk of endometrial cancer and the formation of blood clots in women. Raloxifen, Chart 3, is a benzothiophene selective oestrogen receptor modulator, which, like tamoxifen, acts as an oestrogen antagonist in the breast. Formally known as LY 156,758 or keoxifen, it was first developed in the early 1980s as a candidate for the treatment of breast cancer [76], However, it performed poorly against tamoxifen in laboratory models, and no further development followed until its ability to maintain bone density in postmenopausal women was recognised. It was approved under the new name of raloxifen for the treatment and prevention of osteoporosis (Evista ) [77, 78],... [Pg.90]

NICE (National Institute for Health and Clinical Excellence) (2005) Bisphosphonates (alendronate, etidronate, risedronate), selective oestrogen receptor modulators (raloxifene) and parathyroid hormone (teriparatide) for the secondary prevention of osteoporotic fragility fractures in postmenopausal women. Available at www.nice.org.uk/nicemedia/pdf/TA087guidance.pdf [Accessed 4 July 2008],... [Pg.140]

Raloxifene is a selective oestrogen receptor modulator (SERM). Its role in osteoporosis is to slow down bone loss. It has been shown to increase bone density by 0.5-1%. It is licensed for the prevention and treatment of postmenopausal osteoporosis. Its side-effects include a small increase in the frequency of hot flushes, leg cramps, peripheral oedema and thrombosis risk (Tanna 2005). [Pg.272]

LY 156758 Evista ) is a non-steroid with antioestrogen activity (a selective oestrogen receptor modulator), prevents bone loss and reduces serum cholesterol in ovariectomized rats. It is a potential therapeutic agent for postmenopausal osteoporosis. [Pg.245]

Osborne CK, Zhao H, Fuqua SAW. Selective oestrogen receptor modulators structure, function, and clinical use. J Clin Oncol 2000 18 3172-86. [Pg.94]

Mitlak BH, Cohen FJ. Selective oestrogen receptor modulators. Drugs 1999 57 653-63. Agnusdei D, lori N. Selective oestrogen receptor modulators (SERMs) effects on multiple organ systems. Curr Med Chem 2000 7 577-84. [Pg.94]

Burger HG. Selective oestrogen receptor modulators. Horm Res 2000 53(suppl 3) 25-29. [Pg.1511]

It is known that Japanese women who maintain a high intake of soy products have a low incidence of breast cancer and few menopausal symptoms. The hypothesis is that phytooestrogens act as natural selective-oestrogen receptor modulators influencing oestrogenic responses in the cardiovascular system, breast and uterus. There is good evidence that eating soy protein lowers cholesterol levels and may help prevent atherosclerosis. Symptoms... [Pg.138]

Pedersen, P.C., Gerrits, M., Watson, N. and Bjarnason, K. (2002) Levormeloxifene safety, pharmacodynamics and pharmacokinetics in healthy postmenopausal women following single and multiple doses of a new selective oestrogen receptor modulator. British Journal of Clinical Pharmacology, 53, 284-295. [Pg.194]

Tanko, L.B., Warming, L., Bagger, Y.Z., Byrjalsen, I., Jensen, S. and Christiansen, C. (2002) Serum placental protein 14 a novel marker of selective oestrogen receptor modulator action on the postmenopausal endometrium. Biomarkers, 7, 257—266. [Pg.194]

There have been some relatively new developments in the treatment of osteoporosis. Selective oestrogen receptor modulators, for example raloxifene mimic the inhibitory effects of oestrogen on osteoclasts. Teriparatide, which is a recombinant fragment of... [Pg.127]

Role of pure anti-oestrogens (fulvestrant) and newer selective oestrogen-receptor modulators. [Pg.118]

ANTI-OESTROGENS AND SELECTIVE OESTROGEN RECEPTOR MODULATORS... [Pg.619]

ANTI-OESTROGENS AND SELECTIVE OESTROGEN RECEPTOR MODULATORS [SEDA-31, 664 SEDA-32, 743 SEDA-33, 859 SEDA-34, 669 SEDA-35, 735]... [Pg.619]

Raloxifene is the only selective oestrogen receptor modulator approved for long-term treatment in the prevention of osteoporotic fractures and for the reduction of invasive breast cancer risk in postmenopausal women. The efficacy and adverse effects of raloxifene as well as its molecular mechanism of action have been recently updated. It is noteworthy that quality-of-life studies demonstrated some favourable effects of raloxifene [32 ]. [Pg.620]

Big Chemical Encyclopedia

Chemical substances, components, reactions, process design ...